Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 52

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 52
---
 We are also offering to each purchaser
whose purchase of Depositary Shares in this offering would otherwise result in the purchaser, together with its affiliates, beneficially
owning more than 4.99% (or, at the election of the purchaser, up to 9.99%) of our outstanding Ordinary Shares immediately following the
consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Units containing Pre-Funded Warrants
in lieu of the Depositary Shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the
election of the purchaser, up to 9.99%) of our outstanding Depositary Shares. For each Pre-Funded Unit we sell (without regard to any
limitation on exercise set forth therein), the number of Units including a Depositary Share we are offering will be decreased on a one-for-one
basis. Because one Series L Warrant is being sold together in this offering with each Depositary Share or, in the alternative, each Pre-Funded
Warrant to purchase one Depositary Share, the number of Series L Warrants sold in this offering will not change as a result of a change
in the mix of the Depositary Shares and Pre-Funded Warrants sold.

The Units have no standalone
rights and will not be certificated or issued as standalone securities. The Depositary Shares or Pre-Funded Warrants and Series L Warrants
comprising the Units are immediately separable and will be issued separately in this offering.

American Depositary Shares

Please see the sections titled
“Description of American Depositary Shares” and “Description of Share Capital” in this prospectus
for a description of the material terms of our American Depositary Shares and the underlying Ordinary Shares and our Articles of Association.

Pre-Funded Warrants and Series L Warrants

The following summary of certain terms and provisions of the Pre-Funded Warrants and Series L Warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the form of Pre-Funded Warrant and the form of Series L Warrant, which will be filed as exhibits to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions set forth in the form of Series L Warrant and form of Pre-Funded Warrant.

Duration, Exercise Price and Form.
The exercise price for the Pre-Funded Warrants is $0.0001 per